周二，Cantor Fitzgerald分析师调整了对Ascendis Pharma（NASDAQ:ASND）股票的估值，将目标价从此前的170美元上调至200美元，同时维持增持评级。此次调整是在Ascendis Pharma发布2024年第四季度财报后做出的，该公司业绩表现超出预期。根据 InvestingPro ...

Cantor Fitzgerald的分析指出，未来一年可能出现多个有利于Metsera估值的催化剂。分析师表示，当前估值可能反映约100%的上涨空间，强调了公司股票的强劲增长前景。分析师设定的目标价为56美元，暗示有显著的上涨潜力。欲了解更多关键指标和见解，请查看 InvestingPro ，其提供MTSR的额外独家提示。

Sharp-nosed credit funds in Sydney have fielded approaches from New York’s Cantor Fitzgerald, which is said to be shopping a ...

Shares of several technology and artificial intelligence (AI) stocks struggled today, due to reports of further export ...

HC Wainwright assumed coverage on shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) in a research note published on ...

By Zaheer Kachwala (Reuters) -Electric-vehicle maker Lucid Group said on Tuesday its Chief Executive Officer Peter Rawlinson ...

Needham & Company LLC reaffirmed their buy rating on shares of Applied Digital (NASDAQ:APLD – Free Report) in a report ...

There is a broad reckoning in Ukraine: Washington can no longer be relied upon as a supporter. But Kyiv still has agency on the battlefield and can seek increased support from Europe. By ...

The United States opposed a resolution demanding Russian withdrawal from Ukraine, but won Security Council approval of one calling for peace without assigning blame, exposing fissures between ...